Replies to post #4813 on Halozyme Therapeutics Inc (HALO)

[biotech2020]

Deutsche Bank initiates Halozyme Therapeutics as a buy with a $12 target. Halo is clearly oversold so that's not much of reach, but we are due for a reversal (as are most small cap biotechs). Rituximab approval in the U.S. next year should give a nice boost to the royalty income.